A case report of HER2-positive breast cancer with failed treatment of DS-8201 with post treatment with Initumumab
Anti-human epidermal growth factor receptor 2(HER2)therapy is the standard treatment for patients with advanced breast cancer with positive HER2.The treatment strategy for patients who are resistant to multi-line anti-HER2 therapy is still being explored.A case of breast cancer with multiple metastases after operation is reported in this paper.The adjuvant therapy and first-line therapy are based on trastuzumab,and then fail to receive multi-line anti-HER2 therapy,including the treatments based on pyrrolitinib and antibody-drug conjugates(ADC)therapy(A166,DS-8201),etc.Initumumab combined with Utedelon and Gemcitabine is applied in the seventh line.The patient achieves partial remission at the first efficacy evaluation.Follow-up until April 2023 showed the patient's disease-free survival time has been 10 months.Initumumab combined with Utedelon and Gemcitabine still has good efficacy on this case of HER2 positive advanced breast cancer who fails to be treated by DS-8201.
InitumumabUtedelonGemcitabineDS-8201Anti-HER2 therapyHER2 positive breast cancer
万方数据
维普
